A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose

NCT07102095 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Insufficiency
Liver Diseases
Pharmacokinetics
Drug Metabolism

Interventions

DRUG: Sevabertinib

Sponsor

Bayer